Diabetic Macular Oedema
An Introduction to Diabetic Macular Oedema
The introduction of anti-vascular endothelial growth factor (anti-VEGF) therapies changed the standard of care for patients with diabetic macular oedema, however, the need for longer-acting medications and novel therapeutic targets still exist. Looking to the future, new treatments targeting multiple pathways are currently under investigation.
Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Diabetic Macular Oedema Content
Jakob Grauslund, EURETINA 2022: Navigated laser in Diabetic Macular Oedema and Proliferative Diabetic Retinopathy
It was great to catch up with Prof. Jakob Grauslund (Odense University Hospital, Odense, Denmark) to discuss the advantages of navigated laser photocoagulation systems and their advantages over traditional retinal laser for the treatment of diabetic macular oedema and proliferative diabetic retinopathy. The abstract ‘Navigated laser in DME and PDR?’ was presented at EURETINA 2022, […]
Addressing unmet needs in DME
Watch leading experts discussing the multifactorial nature of DME, and the real-world limitations and burden of existing treatment approaches
Lloyd Clark, Kiaweh Eye 2021: Improvements in the Long-term Management of Diabetic Retinopathy and Diabetic Macular Oedema
It was a pleasure to speak with Lloyd Clark (Palmetto Retina Center, West Columbia, SC, USA) about injection protocols demonstrating improvements in the long-term management of diabetic retinopathy and diabetic macular oedema, and his views on current treatment trends. Questions What injection protocols have demonstrated improvements in the long-term management of diabetic retinopathy and diabetic […]
Felix Datlinger, ARVO 2021: Indocyanine Green Angiography-guided Laser Therapy of Teleangiectatic Capillaries
It was a pleasure to catch up with Felix Datlinger (Medical University of Vienna, Vienna, Austria) about his study on functional and morphological long-term outcomes of indocyanine green angiography-guided laser therapy of teleangiectatic capillaries. Questions What was previously known about the functional and morphological long-term outcomes of indocyanine green angiography-guided laser therapy of teleangiectatic capillaries? […]
Felix Datlinger, ARVO 2021: Teleangiectatic Capillaries in Diabetic Macular Oedema
We were pleased to speak with Felix Datlinger (Medical University of Vienna, Vienna, Austria) about teleangiectatic capillaries in diabetic macular oedema and their clinical significance. Questions How common are teleangiectatic capillaries in diabetic macular edema and what is their clinical significance? (00:25) How are teleangiectatic capillaries diagnosed and treated? (01:04) What are the limitations in […]
Ramin Khoramnia, WOC 2020 – STAIRWAY Phase 2 Trial
Ramin Khoramnia (University Eye Clinic Heidelberg, Heidelberg, Germany) discusses imitations of current treatment options for neovascular age-related macular degeneration, gives an overview of faricimab, its dosing regimen and its mechanism of action and discusses the major efficacy and safety findings of the STAIRWAY study, which were presented at WOC 2020. 1. What are the limitations […]
Aditya Sudhalkar, EURETINA 2019 – Latest research on the use of intravitreal steroids in DME
We met up with Aditya Sudhalkar at EURETINA 2019 to discuss his latest research into treating patients with intravitreal dexamethasone and to learn about his experiences as a rising-star in the field. Support: The production of this video was supported by Allergan, who had no involvement with the development of the content. Filmed at the […]
Samantha Fraser-Bell, EURETINA 2019 – Results of the AUSSIDEX study
Samantha Fraser-Bell (University of Sydney) caught up with us to share the latest results of the AUSSIDEX study, and discuss the real-world impact on patients with DME. Questions: 1. What are the main challenges you face when treating patients with diabetic macular oedema? (0:04) 2. Tell us about your current research in this area (0:31) […]
David Pelayes, EURETINA 2019 – Treatment approaches to DME
David Pelayes (Professor of Ophthalmology, Medical Faculty Mannheim, Ruprecht-Karls-University, Heidelberg, Germany) discusses the current limitations with treatment approaches to DME and the evolving use of OCT-A to predict the response a patient have to DEM treatment. Questions: 1. What recent advances in ophthalmology have had the biggest impact on your practice? 2. What are the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!